Skip to main
JNJ
JNJ logo

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 20%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson reported innovative medicine revenues of $15.20 billion in Q2 2025, surpassing consensus expectations, driven by strong performance in key therapeutic areas such as immunology, oncology, and neurology. The company's management also raised their FY25 sales guidance to $93.2–$93.6 billion, attributing approximately $900 million of the increase to operational growth and roughly $1.1 billion to favorable currency fluctuations, indicating robust demand and operational efficiency. Additionally, JNJ's MedTech division achieved revenues of $8.54 billion, reflecting a 4.1% year-over-year operational growth, contributing to an overall optimistic outlook for sales growth in the second half of 2025 and into 2026.

Bears say

The analysis indicates a negative outlook for Johnson & Johnson's stock primarily due to various operational pressures and uncertainties in their pharmaceutical and MedTech segments. The orthopedics and spine sales dynamics reflect challenges such as competitive headwinds and supply chain disruptions, contributing to a forecast of less than $57 billion in ex-fx revenue for 2025, compounded by lower expectations for product uptake and potential M&A integration disruptions. Additionally, the company faces risks from disappointing product launches, declining sales from key medications nearing patent expirations, and higher-than-anticipated litigation costs, which collectively undermine confidence in its growth trajectory moving forward.

JNJ has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 20% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 15 analysts, JNJ has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.